Are Analysts Bullish about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) after last week?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Logo
Investors sentiment increased to 1.43 in Q1 2019. Its up 0.35, from 1.08 in 2018Q4. It improved, as 23 investors sold Sarepta Therapeutics, Inc. shares while 88 reduced holdings. 57 funds opened positions while 102 raised stakes. 74.26 million shares or 13.02% more from 65.70 million shares in 2018Q4 were reported.
Vanguard Inc holds 0.03% or 6.00M shares. Jennison Assocs owns 0.12% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 1.01M shares. Macquarie Group Limited owns 350,097 shares or 0.07% of their US portfolio. Barclays Public Ltd Co has 0% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) for 56,271 shares. Jane Street Grp Limited Liability invested 0.01% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Jefferies Grp Ltd Liability Company owns 14,845 shares for 0.01% of their portfolio. Jgp Gestao De Recursos Ltda invested in 0.35% or 7,914 shares. Envestnet Asset Mngmt Inc has invested 0% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). The Korea-based Korea Investment has invested 0.02% in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). M&T Financial Bank holds 4,056 shares or 0% of its portfolio. Cubist Systematic Strategies Limited has 0.06% invested in Sarepta Therapeutics, Inc. (NASDAQ:SRPT). Castleark Mngmt Lc accumulated 11,210 shares or 0.05% of the stock. Mirae Asset Ltd holds 0% or 4,195 shares. Balyasny Asset Mgmt Limited Liability Corp holds 159,905 shares or 0.13% of its portfolio. 2,023 were accumulated by Exane Derivatives.

Since August 12, 2019, it had 2 insider buys, and 0 insider sales for $2.16 million activity. On Monday, August 12 the insider Barry Richard bought $159,250.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Ratings Coverage

Among 15 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 15 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Sarepta Therapeutics has $270 highest and $16500 lowest target. $203.56’s average target is 66.89% above currents $121.97 stock price. Sarepta Therapeutics had 33 analyst reports since February 19, 2019 according to SRatingsIntel. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by Janney Capital on Thursday, February 28. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has “Buy” rating given on Friday, March 8 by H.C. Wainwright. Credit Suisse maintained Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rating on Monday, March 11. Credit Suisse has “Buy” rating and $207 target. The rating was maintained by Morgan Stanley on Monday, March 4 with “Overweight”. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by Cantor Fitzgerald on Tuesday, June 25. The stock of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) earned “Buy” rating by Piper Jaffray on Wednesday, February 27. H.C. Wainwright maintained it with “Buy” rating and $267 target in Monday, March 25 report. The firm earned “Buy” rating on Wednesday, February 27 by H.C. Wainwright. On Monday, March 25 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Citigroup maintained the shares of SRPT in report on Tuesday, March 26 with “Buy” rating. Below is a list of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) latest ratings and price target changes.

09/07/2019 Broker: Inc. – Common Stock Rating: Morgan Stanley New Target: $165.0000 220.0000
01/07/2019 Broker: Inc. – Common Stock Rating: Rbc Capital New Target: $188.0000 220.0000
25/06/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $231 Maintain
21/06/2019 Broker: Piper Jaffray Rating: Buy New Target: $208 Maintain
16/05/2019 Broker: Inc. – Common Stock Rating: Citigroup New Target: $201.0000 190.0000
09/05/2019 Broker: Inc. – Common Stock Rating: Rbc Capital New Target: $191.0000 188.0000
26/04/2019 Broker: BidaskScore Rating: Hold Upgrade
12/04/2019 Broker: Evercore Rating: Outperform New Target: $175 Initiates Coverage On
26/03/2019 Broker: Citigroup Rating: Buy New Target: $201 Maintain
25/03/2019 Broker: J.P. Morgan Rating: Buy Maintain

The stock decreased 1.31% or $1.62 during the last trading session, reaching $121.97. About 962,745 shares traded. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has risen 29.09% since August 15, 2018 and is uptrending. It has outperformed by 29.09% the S&P500.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA therapeutics for the treatment of rare neuromuscular diseases. The company has market cap of $9.07 billion. The firm offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy , which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It currently has negative earnings. It also develops SRP-4045 and SRP-4053, which are exon skipping clinical product candidates for the treatment of DMD.

More notable recent Sarepta Therapeutics, Inc. (NASDAQ:SRPT) news were published by: which released: “Health Care Sector Update for 03/06/2019: LGND,NVS,INFI,HCR,VSTM,SRPT – Nasdaq” on March 06, 2019, also with their article: “Is Sarepta Therapeutics (SRPT) Stock Outpacing Its Medical Peers This Year? – Nasdaq” published on July 18, 2019, published: “Sarepta Therapeutics – Buy The Latest ‘Bad News’ – Seeking Alpha” on August 13, 2019. More interesting news about Sarepta Therapeutics, Inc. (NASDAQ:SRPT) were released by: and their article: “Sarepta Therapeutics EPS beats by $0.42, beats on revenue – Seeking Alpha” published on August 07, 2019 as well as‘s news article titled: “Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release – Nasdaq” with publication date: April 25, 2019.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.